Healthcare software provider Health Catalyst (NASDAQ:HCAT) beat analysts' expectations in Q4 FY2023, with revenue up 8.6% year on year to $75.08 million. On the other hand, next quarter's revenue guidance of $74.5 million was less impressive, coming in 5.4% below analysts' estimates. It made a non-GAAP profit of $0.02 per share, improving from its loss of $0.05 per share in the same quarter last year.
Is now the time to buy Health Catalyst? Find out by reading the original article on StockStory.
Health Catalyst (HCAT) Q4 FY2023 Highlights:
- Revenue: $75.08 million vs analyst estimates of $73.59 million (2% beat)
- EPS (non-GAAP): $0.02 vs analyst estimates of -$0.01 ($0.03 beat)
- Revenue Guidance for Q1 2024 is $74.5 million at the midpoint, below analyst estimates of $78.75 million
- Management's revenue guidance for the upcoming financial year 2024 is $308 million at the midpoint, missing analyst estimates by 5.1% and implying 4.1% growth (vs 7.2% in FY2023)
- Free Cash Flow was -$21.92 million, down from $24,000 in the previous quarter
- Gross Margin (GAAP): 40.6%, down from 46.9% in the same quarter last year
- Market Capitalization: $524.9 million
Founded by healthcare professionals Tom Burton and Steve Barlow in 2008, Health Catalyst (NASDAQ:HCAT) provides data and analytics technology to healthcare organizations, enabling them to improve care and lower costs.
Data AnalyticsOrganizations generate a lot of data that is stored in silos, often in incompatible formats, making it slow and costly to extract actionable insights, which in turn drives demand for modern cloud-based data analysis platforms that can efficiently analyze the silo-ed data.
Sales GrowthAs you can see below, Health Catalyst's revenue growth has been unremarkable over the last two years, growing from $64.72 million in Q4 FY2021 to $75.08 million this quarter.
Health Catalyst's quarterly revenue was only up 8.6% year on year, which might disappoint some shareholders. However, we can see that the company's revenue grew by $1.31 million quarter on quarter, re-accelerating from $560,000 in Q3 2023.
Next quarter's guidance suggests that Health Catalyst is expecting revenue to grow 0.9% year on year to $74.5 million, slowing down from the 8.5% year-on-year increase it recorded in the same quarter last year. For the upcoming financial year, management expects revenue to be $308 million at the midpoint, growing 4.1% year on year compared to the 7.1% increase in FY2023.
Cash Is King If you've followed StockStory for a while, you know that we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can't use accounting profits to pay the bills. Health Catalyst burned through $21.92 million of cash in Q4, increasing its cash burn by 20.5% year on year.
Health Catalyst has burned through $46.27 million of cash over the last 12 months, resulting in a negative 15.6% free cash flow margin. This low FCF margin stems from Health Catalyst's constant need to reinvest in its business to stay competitive.
Key Takeaways from Health Catalyst's Q4 Results It was good to see Health Catalyst beat analysts' revenue expectations this quarter. That stood out as a positive in these results. On the other hand, its full-year revenue guidance was below expectations and cash burn increased. Overall, this was a mixed quarter for Health Catalyst. The stock is up 2.6% after reporting and currently trades at $8.69 per share.